STOCK TITAN
  1. Home
  2. News
  3. CANF

Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares - $CANF STOCK NEWS

Welcome to our dedicated page for Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares news (Ticker: $CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares's position in the market.

News
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) received a Notice of Allowance from the European Patent Office for its patent application related to the use of the CF602 drug candidate for the treatment of erectile dysfunction in patients such as diabetics. The patent has already been issued in other major markets. Can-Fite's CF602 showed promising results in a diabetic rat model, offering an alternative for non-responders to current ED drugs. The company sees this as a significant addition to their IP estate, positioning CF602 as a potential treatment for sexual dysfunction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
none
-
News
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
Rhea-AI Summary
Can-Fite BioPharma announced the publication of an article in a scientific journal detailing a long-term complete response to namodenoson in a patient with advanced liver cancer. The patient has been treated for over 7 years, showing improved liver function and quality of life. Can-Fite's Phase III clinical study for namodenoson is ongoing, targeting patients with advanced liver disease. The drug has received Orphan Drug status and Fast Track Status for the treatment of hepatocellular carcinoma (HCC). The market for HCC treatments is expected to grow significantly by 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
-
News
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Rhea-AI Summary
Can-Fite BioPharma announces the publication of a scientific article by a key opinion leader highlighting Namodenoson as a potential treatment for advanced liver cancer and MASH. The article discusses the drug's mechanism of action and its positive effects in liver cancer and MASH, with ongoing Phase III and Phase IIb trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
News
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
Rhea-AI Summary
Can-Fite BioPharma submits IND application to FDA for Phase IIb study of Namodenoson in treating MASH, demonstrating positive effects in reducing hepatic steatosis, inflammation, and fibrosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
clinical trial
-
News
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV
Rhea-AI Summary
Can-Fite BioPharma, (CANF) to present at The 14th Annual LD Micro Invitational in New York. CEO Motti Farbstein to lead the presentation on April 9th, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags
conferences
-
News
Can-Fite Reports 2023 Financial Results and Clinical Update
Rhea-AI Summary
Can-Fite BioPharma announced financial results and clinical updates for the twelve months ended December 31, 2023. Ewopharma acquired marketing rights for Namodenoson in the treatment of pancreatic carcinoma. Can-Fite broadened its IP for NASH, received a patent allowance in Canada, and published positive data for Piclidenoson in a Phase III Psoriasis study. Financially, the company reported a decrease in revenues but a decrease in net loss for the year ended December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
earnings
News
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Rhea-AI Summary
Can-Fite BioPharma Ltd. announces VP of Business Development to present data from pancreatic and liver cancer programs at BIO-Europe Spring 2024. Can-Fite's pipeline includes Namodenoson for liver and pancreatic cancer, licensed to various companies worldwide, attracting interest from potential partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
none
-
News
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
Rhea-AI Summary
Can-Fite BioPharma Ltd. (CANF) receives a Notice of Allowance from the Canadian Intellectual Property Office for a patent related to treating fatty liver disease with Namodenoson. The company's drug reduced liver fat content, showed anti-inflammatory effects, and decreased body weight in patients with NASH in a successful Phase IIa study. Can-Fite's Namodenoson is licensed for NASH treatment in various territories, and the company also has a distribution agreement for its anti-inflammatory drug, Piclidenoson, for psoriasis treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
-
News
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
Rhea-AI Summary
Can-Fite BioPharma Ltd. expands its out licensing transaction with Ewopharma AG to include the pancreatic cancer indication for Piclidenoson and Namodenoson. Ewopharma AG paid Can-Fite an upfront payment of US$2.25 million with up to an additional US$40.45 million, plus 17.5% royalties on net sales. The distribution agreement allows Ewopharma AG to market and sell the drugs in CEE countries and Switzerland. Can-Fite is pleased with the expansion and considers it an important transaction for the company's penetration into Ewopharma's territory.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
News
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
Rhea-AI Summary
Can-Fite BioPharma Ltd. announces the publication of a phase 3 clinical trial for piclidenoson in plaque psoriasis in the Journal of the European Academy of Dermatology and Venereology. The study met its primary endpoint, showing significant improvement in Psoriasis Area and Severity Index (PASI) scores. The drug demonstrated excellent safety and tolerability and is currently being evaluated in a pivotal Phase III study approved by the FDA and EMA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
clinical trial
Stock CANF logo
Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares

NYSE:CANF

CANF Rankings

#5406 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

CANF Stock Data

10.08M
1.50B
4.89%
0.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
P O Box 7537

About CANF

can fite biopharma (canfy) is a biotechnology company based out of 10 bareket street, פ"ת, israel.